A pivotal failure sees the group tinker with a second phase 3 trial, and the delay looks like good news for Bausch.
Deals will come into even greater focus after the failure of ligelizumab, one of the group’s brightest pipeline hopes.
Lack of clarity on safety and efficacy causes shareholders to decamp.
The company’s new osteoporosis formulation is not a patch on the original.
Ingrezza could have some advantages over approved therapies, but a more important Huntington’s readout nears.
The Canadian subsidiary claims success in its pivotal trial, though capacity restraints will limit the jab’s role for now.